HER2-positive Breast CancerPhase 2NCT07856303
SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete Response
A Phase 2 study testing SHR-A1811, Trastuzumab and Pertuzumab in people with HER2-positive Breast Cancer and Early Breast Cancer (EBC), run by Fudan University at 1 site in China.
Trial summary
This investigator-initiated, single-center, randomized, open-label, phase II trial will evaluate the efficacy and safety of intensified adjuvant SHR-A1811 compared with trastuzumab plus pertuzumab in women with initially stage IIB-IIIC HER2-positive early breast cancer who achieved pathologic complete response after… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- HER2-positive Breast Cancer, Early Breast Cancer (EBC)
- What is being tested?
- SHR-A1811, Trastuzumab and Pertuzumab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 358 participants
- Where
- 1 siteChina
- Study dates
- 1 Oct 2026to Aug 2034
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Written informed consent before any study-specific procedure and willingness to comply with study visits and sample collection.
- Female, aged 18 years or older.
- Histologically confirmed invasive breast carcinoma at initial diagnosis, without distant metastasis.
- HER2-positive tumor at initial diagnosis, defined as IHC 3+ or IHC 2+ with ISH amplification; hormone receptor status must be known.
- Initial clinical anatomic stage IIB-IIIC according to the AJCC 8th edition.
- Completion of at least 6 cycles and at least 16 weeks of standard neoadjuvant systemic therapy.
Show all 15Show fewer
- Definitive breast surgery and appropriate axillary staging or dissection, with pathologically complete resection.
- Pathologic complete response, defined as no residual invasive carcinoma in the breast or regional lymph nodes (ypT0/is ypN0); residual ductal carcinoma in situ is permitted.
- Postoperative ctDNA positivity confirmed by the designated central testing laboratory 14-42 days after the last definitive surgery and before initiation of any adjuvant systemic therapy.
- No clinical, pathologic, or radiographic evidence of locoregional recurrence or distant metastasis before randomization; baseline chest CT is required to assess interstitial lung disease/noninfectious pneumonitis.
- Randomization within 12 weeks after the last definitive surgery; extension to 14 weeks may be permitted for documented surgical complications, reoperation, or sequential radiotherapy with principal investigator approval.
- ECOG performance status 0 or 1.
- Left ventricular ejection fraction at least 50% within 28 days before randomization, without clinically significant cardiac dysfunction.
- Adequate bone marrow, hepatic, renal, and coagulation function.
- Negative pregnancy test for participants of childbearing potential and agreement to use highly effective contraception for the protocol-specified period.
Who cannot join
- Clinical, radiographic, or pathologic evidence of unresectable locally advanced, recurrent, or metastatic disease, or disease progression during neoadjuvant therapy.
- Failure to achieve ypT0/is ypN0 or any residual invasive carcinoma in the breast or regional lymph nodes.
- Prior ipsilateral or contralateral breast cancer, including ductal carcinoma in situ; lobular carcinoma in situ is permitted.
- Any postoperative systemic anticancer therapy before randomization, including trastuzumab, pertuzumab, another anti-HER2 agent, chemotherapy, antibody-drug conjugate, or endocrine therapy; bridging therapy is not permitted.
- Prior neoadjuvant treatment with T-DM1, trastuzumab deruxtecan, SHR-A1811, or another HER2-directed antibody-drug conjugate.
- Prior or current interstitial lung disease/noninfectious pneumonitis requiring corticosteroid treatment, active interstitial lung disease on screening imaging, clinically significant pulmonary fibrosis, severe chronic obstructive pulmonary disease, resting hypoxemia, or another pulmonary disorder that would interfere with pulmonary toxicity assessment.
Show all 13Show fewer
- Clinically significant cardiovascular disease, including symptomatic heart failure or NYHA class II-IV heart failure, myocardial infarction or unstable angina within 6 months before screening, uncontrolled clinically significant arrhythmia, QTcF greater than 470 ms, or blood pressure above 150/90 mmHg despite appropriate treatment.
- Active or uncontrolled infection requiring systemic treatment, or active HBV/HCV or HIV not meeting protocol and institutional control criteria.
- Toxicities from prior therapy not recovered to grade 1 or lower, except alopecia, hyperpigmentation, and stable grade 2 peripheral neuropathy judged clinically insignificant by the investigator.
- Another malignancy within 5 years before screening, except adequately treated basal or squamous cell skin cancer, cervical carcinoma in situ, or another malignancy with a low risk of recurrence.
- Severe hypersensitivity to a study drug or any of its excipients.
- Pregnancy, breastfeeding, or plans for pregnancy during the protocol-specified period.
- Any serious medical or psychosocial condition that, in the investigator's judgment, would make study treatment, follow-up, or interpretation of results unsafe or unreliable.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai
Shanghai
Zhimin Shao, 86-021-641755901105, zhimingshao@yahoo.com
Lei Fan, 86-021-641755901105, cmchen@medmail.com.cn
About this study
Official title: A Randomized, Open-Label, Phase II Study of Intensified Adjuvant SHR-A1811 Versus Trastuzumab Plus Pertuzumab in Patients With Initially Stage IIB-IIIC HER2-Positive Early Breast Cancer Who Achieved Pathologic Complete Response After Neoadjuvant Therapy and Have Postoperative ctDNA Positivity
This investigator-initiated, single-center, randomized, open-label, phase II trial will evaluate the efficacy and safety of intensified adjuvant SHR-A1811 compared with trastuzumab plus pertuzumab in women with initially stage IIB-IIIC HER2-positive early breast cancer who achieved pathologic complete response after neoadjuvant systemic therapy and have detectable postoperative circulating tumor DNA (ctDNA). Eligible participants will be randomized 1:1 and stratified by hormone receptor status, HER2 test category, and initial clinical anatomic stage. The primary endpoint is invasive disease-free survival.
Read the detailed description
Patients who have completed neoadjuvant systemic therapy and curative breast and axillary surgery with ypT0/is ypN0 disease will undergo postoperative ctDNA testing 14 to 42 days after the last definitive surgery and before initiation of adjuvant systemic therapy. Participants with ctDNA positivity and no clinical or radiographic evidence of recurrent or metastatic disease will be randomized to SHR-A1811 or trastuzumab plus pertuzumab. Post-randomization ctDNA results will not be used for clinical management and will remain blinded to investigators and participants until the primary analysis database is locked, unless a future ethics-approved protocol amendment specifies otherwise.
- Being tested
- SHR-A1811, Trastuzumab, Pertuzumab
- Keywords
- Circulating Tumor DNA, ctDNA, Minimal Residual Disease, Pathologic Complete Response, Adjuvant Therapy, SHR-A1811
- Medical subject headings
- Breast Neoplasms, Neoplasm, Residual, Pathologic Complete Response
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SHR-A1811Drug
4.8 mg/kg by intravenous infusion once every 3 weeks for 14 cycles.
TrastuzumabDrug
Loading dose: 8 mg/kg IV. Maintenance dose: 6 mg/kg IV Q3W.
PertuzumabDrug
Loading dose: 840 mg IV. Maintenance dose: 420 mg IV Q3W.
| Study group | Role | What they receive |
|---|---|---|
| SHR-A1811 | Experimental | Participants will receive SHR-A1811 4.8 mg/kg by intravenous infusion once every 3 weeks for 14 cycles. Dose interruption and reduction will be managed according to the protocol and study drug management instructions. Receives: Drug: SHR-A1811 |
| Trastuzumab Plus Pertuzumab | Active comparator | Participants will receive trastuzumab plus pertuzumab once every 3 weeks. Including treatment received during the neoadjuvant period, the total perioperative duration of dual HER2-targeted therapy will be approximately 1 year. Receives: Drug: Trastuzumab; Drug: Pertuzumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Invasive Disease-Free Survival (IDFS)
IDFS is defined as the time from randomization to the first occurrence of ipsilateral invasive breast tumor recurrence, regional invasive recurrence, distant recurrence, contralateral invasive breast cancer, secondary invasive primary cancer (nonbreast), or death from any cause.
Measured: At 3 years after randomization
Secondary outcomes (4)
Distant Disease-Free Survival (DDFS)
DDFS is defined as the time from randomization to the first occurrence of distant recurrence, secondary invasive primary cancer (nonbreast), or death from any cause.
Measured: Up to 5 years after randomization
Overall Survival (OS)
Time from randomization to death from any cause.
Measured: Up to 5 years after randomization
Brain Metastasis-Free Interval (BMFI)
Time from randomization to brain metastasis
Measured: Up to 5 years after randomization
Treatment-Emergent Adverse Events
Number and percentage of participants with treatment-emergent adverse events and serious adverse events, graded according to NCI CTCAE version 5.0.
Measured: From randomization through 40 days after the last dose of study treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Oct 2026
- Study start1 Oct 2026 (estimated)
- Primary completionAug 2032 (estimated)
- Study completionAug 2034 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HER2-positive Breast CancerStudies of the same condition, open and under way.
- More trials run by Fudan UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be randomized 1:1 to SHR-A1811 or trastuzumab plus pertuzumab. Randomization will be stratified by hormone receptor status (positive vs negative), HER2 status (IHC 3+ vs IHC 2+/ISH-positive), and initial clinical anatomic stage (IIB vs III)
- Masking
- None (open label)
- Enrolment
- 358 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fudan University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Zhimin Shao, Fudan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07856303
- Sponsor's protocol ID
- SCHBCC-N0123
- Status last verified
- Sep 2026
- First submitted
- 28 Sep 2026
- Last updated
- 2 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Open-Label, Phase II Study of Intensified Adjuvant SHR-A1811 Versus Trastuzumab Plus Pertuzumab in Patients With Initially Stage IIB-IIIC HER2-Positive Early Breast Cancer Who Achieved Pathologic Complete Response After Neoadjuvant Therapy and Have Postoperative ctDNA Positivity
- ClinicalTrials.gov ID
- NCT07856303
- Acronym / sponsor ID
- SCHBCC-N0123
- Keywords
- Circulating Tumor DNA, ctDNA, Minimal Residual Disease, Pathologic Complete Response, Adjuvant Therapy, SHR-A1811
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 358 participants (estimated)
- Lead sponsor
- Fudan UniversityUniversity, hospital or other
- Study start
- 1 Oct 2026 (estimated)
- Primary completion
- Aug 2032 (estimated)
- Study completion
- Aug 2034 (estimated)
- First posted
- 2 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This investigator-initiated, single-center, randomized, open-label, phase II trial will evaluate the efficacy and safety of intensified adjuvant SHR-A1811 compared with trastuzumab plus pertuzumab in women with initially stage IIB-IIIC HER2-positive early breast cancer who achieved pathologic complete response after neoadjuvant systemic therapy and have detectable postoperative circulating tumor DNA (ctDNA). Eligible participants will be randomized 1:1 and stratified by hormone receptor status, HER2 test category, and initial clinical anatomic stage. The primary endpoint is invasive disease-free survival.
Detailed description
Patients who have completed neoadjuvant systemic therapy and curative breast and axillary surgery with ypT0/is ypN0 disease will undergo postoperative ctDNA testing 14 to 42 days after the last definitive surgery and before initiation of adjuvant systemic therapy. Participants with ctDNA positivity and no clinical or radiographic evidence of recurrent or metastatic disease will be randomized to SHR-A1811 or trastuzumab plus pertuzumab. Post-randomization ctDNA results will not be used for clinical management and will remain blinded to investigators and participants until the primary analysis database is locked, unless a future ethics-approved protocol amendment specifies otherwise.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Participants will be randomized 1:1 to SHR-A1811 or trastuzumab plus pertuzumab. Randomization will be stratified by hormone receptor status (positive vs negative), HER2 status (IHC 3+ vs IHC 2+/ISH-positive), and initial clinical anatomic stage (IIB vs III)
| Arm | Type | Receives |
|---|---|---|
| SHR-A1811 | Experimental | Drug: SHR-A1811Participants will receive SHR-A1811 4.8 mg/kg by intravenous infusion once every 3 weeks for 14 cycles. Dose interruption and reduction will be managed according to the protocol and study drug management instructions. |
| Trastuzumab Plus Pertuzumab | Active comparator | Drug: Trastuzumab, Drug: PertuzumabParticipants will receive trastuzumab plus pertuzumab once every 3 weeks. Including treatment received during the neoadjuvant period, the total perioperative duration of dual HER2-targeted therapy will be approximately 1 year. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (15 listed)
- Written informed consent before any study-specific procedure and willingness to comply with study visits and sample collection.
- Female, aged 18 years or older.
- Histologically confirmed invasive breast carcinoma at initial diagnosis, without distant metastasis.
- HER2-positive tumor at initial diagnosis, defined as IHC 3+ or IHC 2+ with ISH amplification; hormone receptor status must be known.
- Initial clinical anatomic stage IIB-IIIC according to the AJCC 8th edition.
Key exclusion criteria (13 listed)
- Clinical, radiographic, or pathologic evidence of unresectable locally advanced, recurrent, or metastatic disease, or disease progression during neoadjuvant therapy.
- Failure to achieve ypT0/is ypN0 or any residual invasive carcinoma in the breast or regional lymph nodes.
- Prior ipsilateral or contralateral breast cancer, including ductal carcinoma in situ; lobular carcinoma in situ is permitted.
- Any postoperative systemic anticancer therapy before randomization, including trastuzumab, pertuzumab, another anti-HER2 agent, chemotherapy, antibody-drug conjugate, or endocrine therapy; bridging therapy is not permitted.
- Prior neoadjuvant treatment with T-DM1, trastuzumab deruxtecan, SHR-A1811, or another HER2-directed antibody-drug conjugate.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SHR-A18114.8 mg/kg by intravenous infusion once every 3 weeks for 14 cycles. | Drug | SHR-A1811 |
| TrastuzumabLoading dose: 8 mg/kg IV. Maintenance dose: 6 mg/kg IV Q3W. | Drug | Trastuzumab Plus Pertuzumab |
| PertuzumabLoading dose: 840 mg IV. Maintenance dose: 420 mg IV Q3W. | Drug | Trastuzumab Plus Pertuzumab |
Primary outcome
Invasive Disease-Free Survival (IDFS)
Time frame: At 3 years after randomization
IDFS is defined as the time from randomization to the first occurrence of ipsilateral invasive breast tumor recurrence, regional invasive recurrence, distant recurrence, contralateral invasive breast cancer, secondary invasive primary cancer (nonbreast), or death from any cause.
4 secondary outcomes
Distant Disease-Free Survival (DDFS)
Time frame: Up to 5 years after randomization
Overall Survival (OS)
Time frame: Up to 5 years after randomization
Brain Metastasis-Free Interval (BMFI)
Time frame: Up to 5 years after randomization
Treatment-Emergent Adverse Events
Time frame: From randomization through 40 days after the last dose of study treatment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for HER2-positive Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Recruiting
Short-Term Reduced Dietary Protein in ER+/HER2- Breast Cancer Patients During Neoadjuvant Chemotherapy
Breast Cancer, Hormone Receptor Positive / HER2-negative Breast Cancer
Active, not recruitingPhase 1/2
Study of Oral MRT-2359 in Selected Cancer Patients
NSCLC, SCLC
RecruitingObservational study
Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer
HR+/HER2- Early Breast Cancer
RecruitingPhase 3
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing SHR-A1811, Trastuzumab and Pertuzumab in people with HER2-positive Breast Cancer and Early Breast Cancer (EBC), run by Fudan University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 15 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 2 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Zhimin Shao (86-021-64175590 ext. 8888, zhimingshao@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Invasive Disease-Free Survival (IDFS) (time frame: At 3 years after randomization). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Oct 2026.